The Incidence and Possible Predictors of Coronary Restenosis

Objective. Assess time and possible predictors of restenosis after the implantation of first- and second-generation coronary stents and bare metal stents (BMSs) in patients with stable coronary artery disease after elective coronary stenting.

Materials and Methods. From 2010 to 2014, 3,732 (2,897 males, 60 [53; 68] years old) patients with stable exertional angina of functional class I–III underwent coronary stenting. From 2014 to 2017, 1,487 (1,173 males and 314 females) patients returned. Repeat coronary angiography was performed in 699 patients.

Results. A total of 644 first-generation stents, 5,321 second-generation stents, and 473 BMSs were implanted. During the control coronary angiography, contrasting was repeated for 193 first-generation stents, 899 second-generation stents, and 77 BMSs. Restenosis (stenosis of 50 % or more in the previously stented segment) was detected in 28 (14 % of angiographic control) first-generation drug-eluting stents, 94 (10 %) second-generation drug-eluting stents, and 21 (27 %) BMSs. Patients with BMS restenosis returned significantly earlier than patients with restenosis of the first- and second-generation drug-eluting stents (11 [6, 27] months vs. 32 [11; 48]) months and 24 [12; 42] months, respectively; p<0.05). The initial and repeat levels of high-sensitivity C-reactive protein (hs-CRP) were higher in patients with restenosis (2.2 [1.2, 5.0] mg / L vs. 2.1 [1.0, 4.6] mg / L, respectively; p> 0.05) than in patients without restenosis (2.0 [0.9, 4.2] mg / L vs. 1.9 [0.7, 3.5] mg / L respectively, p>0.05). Blood levels of hs-CRP ≥2 mg / L according to receiver operating characteristic curve (ROC) analysis at return visit were used as a predictor to identify restenosis of stents with a diameter <3 mm and a length >25 mm – area under the curve (AUC) 0.67 (95 % confidence interval (CI) 0.51–0.84), p <0.05, odds ratio 3.7 (95 % CI 1.1–12.1), p<0.05. Stent type had a significant effect on the time to restenosis in the survival analysis (p<0.0005).

Conclusion. The time from coronary stenting to the return visit of patients presenting with restenosis after the implantation of first- and second-generation drug-eluting stents is consistent; median time of the return visit of patients with restenosis of the first-generation stents was 2–3 years after coronary stenting. Blood levels of hs-CRP ≥2 mg / L at the return visit is a predictor of restenosis of stents with a diameter <3 mm and a length >25 mm.

1. George CJ, Baim DS, Brinker JA, Fischman DL, Goldberg S, Holubkov R et al. One-Year Follow-Up of The Stent Restenosis (STRESS I) Study. The American Journal of Cardiology. 1998;81(7):860–5. DOI: 10.1016/S0002-9149(98)00004-6

2. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F et al. Short and Long-Term Outcomes With Drug-Eluting and BareMetal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-Years of Follow-Up From Randomized Trials. Circulation. 2012;125(23):2873–91. DOI: 10.1161/CIRCULATIONAHA.112.097014

3. Badour SA, Dimitrova KR, Kanei Y, Tranbaugh RF, Hajjar MM, Kabour A et al. First and second generation DESs reduce diabetes adverse effect on mortality and re-intervention in multivessel coronary disease: 9-Year analysis. Cardiovascular Revascularization Medicine. 2017;18(4):265–73. DOI: 10.1016/j.carrev.2017.01.012

4. Mangione FM, Biering-Sørensen T, Nochioka K, Jatene T, Silvestre OM, Hansen KW et al. Second generation drug-eluting stents versus bare-metal stents for percutaneous coronary intervention of the proximal left anterior descending artery: An analysis of the BASKET-PROVE I and II trials. Catheterization and Cardiovascular Interventions. 2018;91(5):867–73. DOI: 10.1002/ccd.27200

5. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O’Shaughnessy C et al. Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. New England Journal of Medicine. 2003;349(14):1315–23. DOI: 10.1056/NEJMoa035071

6. Weisz G, Leon MB, Holmes DR, Kereiakes DJ, Popma JJ, Teirstein PS et al. Five-Year Follow-Up After Sirolimus-Eluting Stent Implantation results of the SIRIUS (sirolimus-eluting stent in de novo native coronary lesions) trial. Journal of the American College of Cardiology. 2009;53(17):1488–97. DOI: 10.1016/j.jacc.2009.01.050

7. Kim YH, Her A-Y, Rha S-W, Choi BG, Choi SY, Byun JK et al. Fiveyear major clinical outcomes between first-generation and secondgeneration drug-eluting stents in acute myocardial infarction patients underwent percutaneous coronary intervention. Journal of geriatric cardiology: JGC. 2018;15(8):523–33. DOI: 10.11909/j.issn.1671-5411.2018.08.006

8. Neumann F-J, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 2019;14(14):1435–534. DOI: 10.4244/EIJY19M01_01

9. Alekyan B.G., Grigor’yan A.M., Staferov A.V., Karapetyan N.G. Endovas- cular diagnostics and treatment in the Russian federation (2018). Rus- sian Journal of Endovascular Surgery. 2019;6(2 Special issue):5s–188s. In Russian

10. Rodriguez AE, Santaera O, Larribau M, Sarmienko R, Haiek C, POZO JFD et al. Second vs. first-generation drug-eluting stents in complex lesions subsets: 3 years’ follow-up of ERACI IV study. Minerva Cardioangiologica. 2016;65(1):81–90. DOI: 10.23736/S00264725.16.04252-3

11. Qian F, Zhong Y, Hannan EL. Long-term comparative effectiveness of paclitaxel-eluting and everolimus-eluting stents in New York. International Journal of Cardiology. 2017;227:490–6. DOI: 10.1016/j.ijcard.2016.10.116

12. Zandvoort LJC, Bommel RJ, Masdjedi K, Tovar Forero MN, Lemmert MM, Wilschut J et al. Long‐term outcome in patients treated with first‐ versus second‐generation drug‐eluting stents for the treatment of unprotected left main coronary artery stenosis. Catheterization and Cardiovascular Interventions. 2019;ccd.28387. [Epub ahead of print]. DOI: 10.1002/ccd.28387

13. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T et al. Very Late Stent Thrombosis and Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation: Five-Year Outcome of the j-Cypher Registry. Circulation. 2012;125(4):584–91. DOI: 10.1161/CIRCULATIONAHA.111.046599

14. Völz S, Angerås O, Odenstedt J, Ioanes D, Haraldsson I, Dworeck C et al. Sustained risk of stent thrombosis and restenosis in first generation drug-eluting Stents after One Decade of Follow-up: A Report from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Catheterization and Cardiovascular Interventions. 2018;92(6):E403–9. DOI: 10.1002/ccd.27655

15. Morice M-C, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M et al. A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization. New England Journal of Medicine. 2002;346(23):1773–80. DOI: 10.1056/NEJMoa012843

16. Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A et al. Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice. Circulation. 2005;112(21):3306–13. DOI: 10.1161/CIRCULATIONAHA.105.552190

17. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D et al. Comparison of a Polymer-Based Paclitaxel-Eluting Stent With a Bare Metal Stent in Patients With Complex Coronary Artery Disease: A Randomized Controlled Trial. JAMA. 2005;294(10):1215–23. DOI: 10.1001/jama.294.10.1215

18. Kereiakes DJ, Cox DA, Hermiller JB, Midei MG, Bachinsky WB, Nukta ED et al. Usefulness of a cobalt chromium coronary stent alloy. The American Journal of Cardiology. 2003;92(4):463–6. DOI: 10.1016/S0002-9149(03)00669-6

19. Nguyen SH, Dang TP, MacPherson C, Maibach H, Maibach HI. Prevalence of patch test results from 1970 to 2002 in a multi-centre population in North America (NACDG). Contact Dermatitis. 2007;58(2):101–6. DOI: 10.1111/j.1600-0536.2007.01281.x

20. Sheiban I. Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V®). Vascular Health and Risk Management. 2008;4(1):31–8. DOI: 10.2147/vhrm.2008.04.01.31

21. Chen JP, Hou D, Pendyala L, Goudevenos JA, Kounis NG. Drug-Eluting Stent Thrombosis: the Kounis hypersensitivity-associated acute coronary syndrome revisited. JACC: Cardiovascular Interventions. 2009;2(7):583–93. DOI: 10.1016/j.jcin.2009.04.017

22. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051–8. DOI: 10.1161/CIRCULATIONAHA.106.675934

23. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK et al. Vascular Responses to Drug Eluting Stents: Importance of Delayed Healing. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(7):1500–10. DOI: 10.1161/ATVBAHA.107.144220

24. Pache J ürgen, Kastrati A, Mehilli J, Schühlen H, Dotzer F, Hausleiter J örg et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. Journal of the American College of Cardiology. 2003;41(8):1283–8. DOI: 10.1016/S0735-1097(03)00119-0

25. Wilson GJ, Nakazawa G, Schwartz RS, Huibregtse B, Poff B, Herbst TJ et al. Comparison of Inflammatory Response After Implantation of Sirolimusand Paclitaxel-Eluting Stents in Porcine Coronary Arteries. Circulation. 2009;120(2):141–9. DOI: 10.1161/CIRCULATIONAHA.107.730010

26. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109(6):701–5. DOI: 10.1161/01.CIR.0000116202.41966.D4

27. Yeh JS, Oh SJ, Hsueh CM. Frequency of Vascular Inflammation and Impact on Neointimal Proliferation of Drug Eluting Stents in Porcine Coronary Arteries. Acta Cardiologica Sinica. 2016;32(5):570–7. DOI: 10.6515/acs20151013g

28. Claessen BE, Stone GW, Mehran R, Witzenbichler B, Brodie BR, Wöhrle J et al. Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy. Journal of Thrombosis and Thrombolysis. 2012;34(2):165–79. DOI: 10.1007/s11239012-0706-x

29. Kazmierczak E, Grajek S, Kowal J, Chmara E, Grygier M, Pyda M et al. Prognostic usefulness of IL-6 and VEGF for the occurrence of changes in coronary arteries of patients with stable angina and implanted stents. European Review for Medical and Pharmacological Sciences. 2014;18(15):2169–75. PMID: 25070823

30. Wang Z, Liu C, Fang H. Blood Cell Parameters and Predicting Coronary In-Stent Restenosis. Angiology. 2019;70(8):711–8. DOI: 10.1177/0003319719830495

31. Haybar H, Sadegh Pezeshki SM, Saki N. Platelets in In-stent Restenosis: From Fundamental Role to Possible Prognostic Application. Current Cardiology Reviews. 2019;15. [Epub ahead of print]. DOI: 10.2174/1573403X15666190620141129

32. Oemrawsingh RM, Cheng JM, Akkerhuis KM, Kardys I, Degertekin M, van Geuns R-J et al. High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. EuroIntervention. 2016;12(3):345–51. DOI: 10.4244/EIJY15M07_04

33. Cheng G, Chang F, Wang Y, You P-H, Chen H, Han W et al. Factors Influencing Stent Restenosis After Percutaneous Coronary Intervention in Patients with Coronary Heart Disease: A Clinical Trial Based on 1-Year Follow-Up. Medical Science Monitor. 2019;25:240–7. DOI: 10.12659/MSM.908692

34. Hsieh I-C, Chen C-C, Hsieh M-J, Yang C-H, Chen D-Y, Chang S-H et al. Prognostic Impact of 9-Month High-Sensitivity C-Reactive Protein Levels on Long-Term Clinical Outcomes and In-Stent Restenosis in Patients at 9 Months after Drug-Eluting Stent Implantation. PLOS ONE. 2015;10(9):e0138512. DOI: 10.1371/journal.pone.0138512

35. Zhu X, Chen Y, Xiang L, You T, Jiao Y, Xu W et al. The long-term prognostic significance of high-sensitive C-reactive protein to instent restenosis. Medicine. 2018;97(27):e10679. DOI: 10.1097/MD.0000000000010679

36. Shiiba M, Zhang B, Miura S, Ike A, Nose D, Kuwano T et al. Association between discordance of LDL-C and non-HDL-C and clinical outcomes in patients with stent implantation: from the FU-Registry. Heart and Vessels. 2018;33(2):102–12. DOI: 10.1007/s00380-017-1036-x

37. Valgimigli M, Tebaldi M, Borghesi M, Vranckx P, Campo G, Tumscitz C et al. Two-Year Outcomes After Firstor Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary Intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia study). JACC: Cardiovascular Interventions. 2014;7(1):20–8. DOI: 10.1016/j.jcin.2013.09.008

38. Smits PC, Vlachojannis GJ, McFadden EP, Royaards K-J, Wassing J, Joesoef KS et al. Final 5-Year Follow-Up of a Randomized Controlled Trial of Everolimusand Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice. JACC: Cardiovascular Interventions. 2015;8(9):1157–65. DOI: 10.1016/j.jcin.2015.03.028

39. Wu G, Sun G, Zhao R, Sun M. Systematic review/Meta-analysis Clinical outcomes of secondversus first-generation drug-eluting stents in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Archives of Medical Science. 2014;10(4):643–50. DOI: 10.5114/aoms.2014.44855